BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25386760)

  • 1. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.
    Wang LY; Smith AW; Palmer FL; Tuttle RM; Mahrous A; Nixon IJ; Patel SG; Ganly I; Fagin JA; Boucai L
    Thyroid; 2015 Mar; 25(3):300-7. PubMed ID: 25386760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
    Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
    Biondi B; Cooper DS
    Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma".
    Schneider P; Schneider R; Schneider M; Reiners C
    Thyroid; 2015 Nov; 25(11):1267-8. PubMed ID: 26192011
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to: Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma".
    Boucai L; Wang LY; Smith AW; Palmer FL; Mahrous A; Tuttle RM; Fagin JA
    Thyroid; 2015 Nov; 25(11):1269-70. PubMed ID: 26359968
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer.
    Klubo-Gwiezdzinska J; Auh S; Gershengorn M; Daley B; Bikas A; Burman K; Wartofsky L; Urken M; Dewey E; Smallridge R; Chindris AM; Kebebew E
    JAMA Netw Open; 2019 Feb; 2(2):e187754. PubMed ID: 30707227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.
    Park S; Kim WG; Han M; Jeon MJ; Kwon H; Kim M; Sung TY; Kim TY; Kim WB; Hong SJ; Shong YK
    Thyroid; 2017 Sep; 27(9):1164-1170. PubMed ID: 28699428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
    Xia Q; Dong S; Bian PD; Wang J; Li CJ
    Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer.
    Jonklaas J; Nsouli-Maktabi H; Soldin SJ
    Thyroid; 2008 Sep; 18(9):943-52. PubMed ID: 18788918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
    Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
    Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
    Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
    Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
    Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
    Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Thyroid-Stimulating Hormone Suppression on Muscle Function After Total Thyroidectomy in Patients With Thyroid Cancer.
    Lee JC; Song BS; Kang YM; Kim YR; Kang YE; Lee JH; Shong M; Yi HS
    Front Endocrinol (Lausanne); 2021; 12():769074. PubMed ID: 34858341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer.
    Abonowara A; Quraishi A; Sapp JL; Alqambar MH; Saric A; O'Connell CM; Rajaraman MM; Hart RD; Imran SA
    Clin Invest Med; 2012 Jun; 35(3):E152-6. PubMed ID: 22673318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
    Do Cao C; Wémeau JL
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body Composition, Resting Energy Expenditure, and Metabolic Changes in Women Diagnosed with Differentiated Thyroid Carcinoma.
    Izkhakov E; Vaisman N; Barnes S; Barchana M; Stern N; Keinan-Boker L
    Thyroid; 2019 Aug; 29(8):1044-1051. PubMed ID: 31088334
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma].
    Miyakawa M
    Nihon Rinsho; 2007 Nov; 65(11):2073-7. PubMed ID: 18018573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.